论文部分内容阅读
目的:探讨选择低分子肝素对慢性阻塞性肺疾病急性加重期患者给予早期治疗干预后获得的临床效果。方法:选择我院2014年01月~2016年09月收治的慢性阻塞性肺疾病急性加重期患者120例作为研究对象;所有慢性阻塞性肺疾病急性加重期患者选择抽签分组的方法;对照组:常规治疗;观察组:常规治疗+早期低分子肝素治疗;对比PaCO_2以及PaO_2等指标方面表现出的差异。结果:在PaCO_2以及PaO_2指标表现方面,观察组优于对照组慢性阻塞性肺炎急性加重期患者非常明显(P<0.05)。结论:对于慢性阻塞性肺疾病急性加重期患者的疾病发展程度加以了解后,于早期合理选择低分子肝素加以治疗干预,可以确保患者的PaCO_2以及PaO_2等指标获得确切改善,最终显著提高慢性阻塞性肺疾病急性加重期患者的疾病治疗效果。
Objective: To investigate the clinical effect of low molecular weight heparin on early treatment intervention in patients with acute exacerbation of chronic obstructive pulmonary disease. Methods: A total of 120 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to our hospital from January 2014 to September 2016 were enrolled in this study. All patients with chronic obstructive pulmonary disease Conventional treatment; observation group: conventional treatment + early low molecular weight heparin treatment; compared PaCO_2 and PaO_2 and other indicators showed differences. Results: In the PaCO_2 and PaO_2 indicators, the observation group was superior to the control group in patients with acute exacerbation of COPD (P <0.05). CONCLUSIONS: To understand the extent of disease progression in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD), rational selection of low molecular weight heparin for therapeutic intervention in the early stage can ensure that the patients’ PaCO 2 and PaO 2 indexes are improved and finally improve the chronic obstructive Acute exacerbation of lung disease in patients with disease treatment.